- Home
- LCTX vs PZC Comparison
LCTX vs PZC Comparison
Compare LCTX & PZC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- PZC
- Stock Information
- Founded
- LCTX 1990
- PZC 2002
- Country
- LCTX United States
- PZC United States
- Employees
- LCTX N/A
- PZC N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- PZC Investment Managers
- Sector
- LCTX Health Care
- PZC Finance
- Exchange
- LCTX Nasdaq
- PZC Nasdaq
- Market Cap
- LCTX 166.3M
- PZC 168.0M
- IPO Year
- LCTX N/A
- PZC N/A
- Fundamental
- Price
- LCTX $0.91
- PZC $7.12
- Analyst Decision
- LCTX Strong Buy
- PZC
- Analyst Count
- LCTX 3
- PZC 0
- Target Price
- LCTX $5.67
- PZC N/A
- AVG Volume (30 Days)
- LCTX 442.0K
- PZC 48.2K
- Earning Date
- LCTX 11-14-2024
- PZC 01-01-0001
- Dividend Yield
- LCTX N/A
- PZC 4.68%
- EPS Growth
- LCTX N/A
- PZC N/A
- EPS
- LCTX N/A
- PZC N/A
- Revenue
- LCTX $6,186,000.00
- PZC N/A
- Revenue This Year
- LCTX N/A
- PZC N/A
- Revenue Next Year
- LCTX $123.52
- PZC N/A
- P/E Ratio
- LCTX N/A
- PZC N/A
- Revenue Growth
- LCTX N/A
- PZC N/A
- 52 Week Low
- LCTX $0.77
- PZC $6.30
- 52 Week High
- LCTX $1.61
- PZC $8.20
- Technical
- Relative Strength Index (RSI)
- LCTX 55.63
- PZC 36.83
- Support Level
- LCTX $0.88
- PZC $7.11
- Resistance Level
- LCTX $0.97
- PZC $7.24
- Average True Range (ATR)
- LCTX 0.04
- PZC 0.07
- MACD
- LCTX 0.01
- PZC -0.01
- Stochastic Oscillator
- LCTX 71.56
- PZC 12.15
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About PZC PIMCO California Municipal Income Fund III of Beneficial Interest
PIMCO CA Muni Income Fund III operates as a closed-end management investment company. The investment objective of the fund is to seek to provide current income exempt from federal and California income tax. Its portfolio of investments includes investment in different sectors such as education, healthcare, industrial and others.